NCT01861496: Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours

NCT01861496
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1|Ph+ase 2
Drug Category: Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Known or suspected active central nervous system (CNS metastasis). Patients stable 8 weeks after completion of treatment for CNS metastasis are eligible.
https://ClinicalTrials.gov/show/NCT01861496

Comments are closed.

Up ↑